-
Something wrong with this record ?
Targeting virulence of resistant Escherichia coli by the FDA-approved drugs sitagliptin and nitazoxanide as an alternative antimicrobial approach
SM. Eltabey, AH. Ibrahim, MM. Zaky, AE. Ibrahim, YBA. Alrashdi, S. El Deeb, MM. Saleh
Language English Country Czech Republic
Document type Journal Article
- MeSH
- Anti-Bacterial Agents * pharmacology MeSH
- Biofilms drug effects MeSH
- Nitro Compounds MeSH
- Escherichia coli * drug effects pathogenicity genetics MeSH
- Virulence Factors genetics metabolism MeSH
- Escherichia coli Infections * drug therapy microbiology MeSH
- Humans MeSH
- Microbial Sensitivity Tests MeSH
- Drug Resistance, Multiple, Bacterial MeSH
- Mice MeSH
- Escherichia coli Proteins genetics MeSH
- Sitagliptin Phosphate * pharmacology MeSH
- Thiazoles * pharmacology MeSH
- Virulence drug effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
The spread of multidrug-resistant Escherichia coli in healthcare facilities is a global challenge. Hospital-acquired infections produced by Escherichia coli include gastrointestinal, blood-borne, urinary tract, surgical sites, and neonatal infections. Therefore, novel approaches are needed to deal with this pathogen and its rising resistance. The concept of attenuating virulence factors is an alternative strategy that might lead to low levels of resistance and combat this pathogen. A sub-inhibitory concentration (1⁄4 MIC) of sitagliptin and nitazoxanide was used for phenotypic assessments of Escherichia coli virulence factors such as biofilm production, swimming motility, serum resistance, and protease production. Moreover, qRT-PCR was used to determine the impact of sub-MIC of the tested drugs on the relative expression levels of papC, fimH, fliC, kpsMTII, ompT_m, and stcE genes encoding virulence factors in Escherichia coli. Also, an in vivo model was conducted as a confirmatory test. Phenotypically, our findings demonstrated that the tested strains showed a significant decrease in all the tested virulence factors. Moreover, the genotypic results showed a significant downregulation in the relative expression levels of all the tested genes. Besides, the examined drugs were found to be effective in protecting mice against Escherichia coli pathogenesis. Sitagliptin and nitazoxanide exhibited strong anti-virulence activities against Escherichia coli. In addition, it is recommended that they might function as adjuvant in the management of Escherichia coli infections with either conventional antimicrobial agents or alone as alternative treatment measures.
Botany Department Faculty of Science Port Said University Port Said Egypt
College of Pharmacy and Nursing University of Nizwa Birkat Al Mauz Nizwa 616 Oman
Faculty of Pharmacy Ashour University Baghdad Iraq
Microbiology and Immunology Department Faculty of Pharmacy Port Said University Port Said Egypt
Microbiology Program Botany Department Faculty of Science Port Said University Port Said Egypt
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25017865
- 003
- CZ-PrNML
- 005
- 20250814134149.0
- 007
- ta
- 008
- 250814s2025 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12223-024-01215-7 $2 doi
- 035 __
- $a (PubMed)39470968
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Eltabey, Sara M $u Microbiology Program, Botany Department, Faculty of Science, Port Said University, Port Said, Egypt
- 245 10
- $a Targeting virulence of resistant Escherichia coli by the FDA-approved drugs sitagliptin and nitazoxanide as an alternative antimicrobial approach / $c SM. Eltabey, AH. Ibrahim, MM. Zaky, AE. Ibrahim, YBA. Alrashdi, S. El Deeb, MM. Saleh
- 520 9_
- $a The spread of multidrug-resistant Escherichia coli in healthcare facilities is a global challenge. Hospital-acquired infections produced by Escherichia coli include gastrointestinal, blood-borne, urinary tract, surgical sites, and neonatal infections. Therefore, novel approaches are needed to deal with this pathogen and its rising resistance. The concept of attenuating virulence factors is an alternative strategy that might lead to low levels of resistance and combat this pathogen. A sub-inhibitory concentration (1⁄4 MIC) of sitagliptin and nitazoxanide was used for phenotypic assessments of Escherichia coli virulence factors such as biofilm production, swimming motility, serum resistance, and protease production. Moreover, qRT-PCR was used to determine the impact of sub-MIC of the tested drugs on the relative expression levels of papC, fimH, fliC, kpsMTII, ompT_m, and stcE genes encoding virulence factors in Escherichia coli. Also, an in vivo model was conducted as a confirmatory test. Phenotypically, our findings demonstrated that the tested strains showed a significant decrease in all the tested virulence factors. Moreover, the genotypic results showed a significant downregulation in the relative expression levels of all the tested genes. Besides, the examined drugs were found to be effective in protecting mice against Escherichia coli pathogenesis. Sitagliptin and nitazoxanide exhibited strong anti-virulence activities against Escherichia coli. In addition, it is recommended that they might function as adjuvant in the management of Escherichia coli infections with either conventional antimicrobial agents or alone as alternative treatment measures.
- 650 12
- $a Escherichia coli $x účinky léků $x patogenita $x genetika $7 D004926
- 650 12
- $a sitagliptin fosfát $x farmakologie $7 D000068900
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a thiazoly $x farmakologie $7 D013844
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a faktory virulence $x genetika $x metabolismus $7 D037521
- 650 12
- $a infekce vyvolané Escherichia coli $x farmakoterapie $x mikrobiologie $7 D004927
- 650 _2
- $a virulence $x účinky léků $7 D014774
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a dusíkaté sloučeniny $7 D009574
- 650 12
- $a antibakteriální látky $x farmakologie $7 D000900
- 650 _2
- $a biofilmy $x účinky léků $7 D018441
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a proteiny z Escherichia coli $x genetika $7 D029968
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mnohočetná bakteriální léková rezistence $7 D024901
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ibrahim, Ali H $u Botany Department, Faculty of Science, Port Said University, Port Said, Egypt
- 700 1_
- $a Zaky, Mahmoud M $u Botany Department, Faculty of Science, Port Said University, Port Said, Egypt
- 700 1_
- $a Ibrahim, Adel Ehab $u Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, P.O. Box 33, Nizwa, 616, Oman. adel@unizwa.edu.om $1 https://orcid.org/0000000174211220
- 700 1_
- $a Alrashdi, Yahya Bin Abdullah $u College of Pharmacy and Nursing, University of Nizwa, Birkat Al Mauz, Nizwa, 616, Oman
- 700 1_
- $a El Deeb, Sami $u Institute of Medicinal and Pharmaceutical Chemistry, Technische Universitaet Braunschweig, Brunswick, Germany. s.eldeeb@tu-bs.de
- 700 1_
- $a Saleh, Moustafa M $u Microbiology and Immunology Department, Faculty of Pharmacy, Port Said University, Port Said, Egypt $u Faculty of Pharmacy, Ashour University, Baghdad, Iraq
- 773 0_
- $w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 70, č. 3 (2025), s. 645-656
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39470968 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250814 $b ABA008
- 991 __
- $a 20250814134139 $b ABA008
- 999 __
- $a ok $b bmc $g 2375089 $s 1255995
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 70 $c 3 $d 645-656 $e 20241029 $i 1874-9356 $m Folia microbiologica $n Folia Microbiol (Praha) $x MED00011005
- LZP __
- $a Pubmed-20250814
